Analyst

PAPER

Check for updates

Cite this: Analyst, 2024, 149, 5139

Received 15th April 2024, Accepted 2nd September 2024 DOI: 10.1039/d4an00569d

rsc.li/analyst

Introduction

Fluorescence polarization (FP), which reflects the rotational diffusion of fluorescent molecules during their lifetime (Fig. 1a), is a versatile property for investigating interactions between molecules in solutions.^{1,2} The FP assay can be used to measure changes in the size of fluorescent molecules without additional processes such as washing. Therefore, it is widely used as a one-step homogeneous assay and is applied to the quantification of various biomolecules in many research fields, such as drug discovery,^{3–5} food safety,^{6,7} and disease diagnosis.⁸

The combination of FP and microfluidic devices reduces reagent consumption, increases analysis throughput, and min-

^dTianma Japan, Ltd., Shin-Kawasaki Mitsui Building West Tower 28F 1-1-2, Kashimada, Saiwai-ku, Kawasaki, Kanagawa 212-0058, Japan

Sensitivity-improved blocking agent-free fluorescence polarization assay through surface modification using polyethylene glycol[†]

Hao Liu, ⁽¹⁾^{a,b} Mao Fukuyama, ⁽¹⁾ *^a Yu Ogura,^a Motohiro Kasuya,^c Sho Onose,^d Ayuko Imai,^d Koji Shigemura,^d Manabu Tokeshi ⁽¹⁾ ^e and Akihide Hibara ⁽¹⁾ *^f

Fluorescence polarization (FP) assays are widely used to quantify biomolecules, and their combination with microfluidic devices has the potential for application in onsite analysis. However, the hydrophobic surface of polydimethylsiloxane (PDMS)-based microfluidic devices and the amphiphilicity of the blocking agents can cause the nonspecific adsorption of biomolecules, which in turn reduces the sensitivity of the FP assay. To address this, we demonstrated an FP assay with improved sensitivity in microfluidic devices using a polyethylene glycol-based surface modification to avoid the use of blocking agents. We evaluated the effectiveness of the modification in inhibiting nonspecific protein adsorption and demonstrated the improved sensitivity of the FP immunoassay (FPIA). Our study addressed the lack of sensitivity of FP assays in microfluidic devices, particularly for the quantification of low-abundance analytes.

iaturizes the system.9-18 High-throughput screening methods examine biomolecular interactions in a time-efficient manner, which is important for understanding biological functions and for drug discovery.^{19,20} Cheow et al. developed a highthroughput protein-ligand binding assay based on FP on a microfluidic platform that could simultaneously interrogate over 2300 interactions.¹¹ The organ-on-a-chip technology simulates the functions of human organs in a controlled environment. Integrating this with the FP assay provides accurate, real-time molecular analysis, which is critical for biomedical research.²¹ A. L. Glieberman et al. designed an "islet on a chip" for continuous, automated insulin quantification through FP assay, enabling high-resolution dynamic analysis.²² Recently, we developed a portable FP analyzer using a polydimethylsiloxane (PDMS)-based microfluidic device for on-site analysis.²³ Using this system, we report the application of an FP immunoassay (FPIA) for various samples such as mycotoxins in wheat, exosomes, and protein biomarkers in serum.^{24–26}

However, although the use of microfluidic devices reduces the sample and reagent volumes, it also limits the sensitivity of FP owing to the nonspecific adsorption of the analyte and tracer molecules to the solid–liquid interface in the device. Although PDMS is a widely used material for fabricating microfluidic devices,^{27,28} hydrophobic and amphiphilic molecules, including proteins and lipids, are non-specifically adsorbed onto the interfaces because PDMS is hydrophobic.²⁹ While hydrophilic surface modification and non-adsorptive materials have been used in both microplates^{30,31} and in



View Article Online

^aInstitute of Multidisciplinary Research for Advanced Materials, Tohoku University, 2-1-1 Katahira, Aoba-ku, Sendai 980-8577, Japan.

E-mail: maofukuyama@tohoku.ac.jp

^bSchool of Science, Tohoku University, 6-3, Aramaki Aza-Aoba, Aoba-ku, Sendai 980-8578, Japan

^cFaculty of Production Systems Engineering and Sciences, Komatsu University, Nu 1-3 Shicho-machi, Komatsu, Ishikawa 923-8511, Japan

^eDivision of Applied Chemistry, Hokkaido University, Kita 13 Nishi 8, Kita-ku, Sapporo 060-8628, Japan

^fDepartment of Chemistry, School of Science, Tokyo Institute of Technology,

²⁻¹²⁻¹ Ookayama, Meguro-ku, Tokyo 152-8551, Japan.

E-mail: hibara.a.aa@m.titech.ac.jp

[†]Electronic supplementary information (ESI) available. See DOI: https://doi.org/ 10.1039/d4an00569d

Paper

Analyst



Fig. 1 Principle of PEG-PDMS to improve sensitivity of FP assays in microfluidic devices. (a) Principle of FP assays. I_{\parallel} and I_{\perp} are the fluorescence intensities of the vertical and horizontal components. (b) Schematic diagram of nonspecific binding between tracer and BSA blocking agent and its standard curve. (c) Schematic diagram of the absence of nonspecific binding in PEG-PDMS and its standard curve. PDMS, polydimethylsiloxane; PEG, polyethylene glycol; FP, fluorescence polarization; BSA, bovine serum albumin.

microfluidic devices,^{32,33} the use of blocking agents still remains a more common practice because it is simpler to implement. In microfluidic bioanalytical applications, blocking agents such as bovine serum albumin (BSA) are typically used to prevent nonspecific adsorption. However, even when blocking agents were used, interference occurred (Fig. 1b). Blocking agents can interfere with immunoreactivity,^{34,35} such as through nonspecific binding of amphiphilic blocking agents with tracers and analytes.^{36,37} In addition, the blocking agent cannot completely cover the solid surface and there is still room for a tracer.³⁸ In this case, the polarization degree (P) change does not reflect the concentration of the analyte because tracer complexation to the blocking agent and its adsorption to the surface increase P and potentially hinder the P increase by analyte-tracer bonding. Although the number of molecules bound to the blocking agents was negligible when the tracer concentration was high, the amount of binding was significant when the concentration was low. Because the tracer concentration must be low to achieve high sensitivity³⁹ (details are explained in Fig. 4a), the use of blocking agents can be critical for FP assay sensitivity.

In this study, we demonstrate an improvement in the sensitivity of the FP assay through surface modification. Using our previously reported polyethylene glycol (PEG)-based modification method, the hydrophobic PDMS surface was modified into a hydrophilic surface by simple one-step mixing of PDMS with PEG-functionalized silicone.⁴⁰ This method requires fewer modifications than other methods that involve multiple coating modifications after PDMS fabrication.41,42 The PEG group contains long chains that exhibit steric repulsion and inhibit protein adsorption.43 This PDMS-PEG copolymer can effectively suppress the nonspecific adsorption of the tracer without the need for blocking agents (Fig. 1c), allowing P to accurately reflect the sample concentration and thus improve sensitivity. We used positively and negatively charged proteins to evaluate the ability and versatility of this modification method to inhibit nonspecific protein adsorption. Sensitivity improvement was demonstrated by FPIA in a PEG-PDMS device with a portable FP analyzer (Fig. 2a).⁴⁴



Fig. 2 Portable fluorescence polarization analyzer and microfluidic device. (a) Picture of the portable fluorescence polarization analyzer. (b) Photo and schematic diagram of the microfluidic device.

Experimental

Chemicals

A Sylgard 184 silicone elastomer kit for the PDMS microdevice fabrication and PEG-functionalized silicone (501 W additive) consisting of heptamethyl-3-(propyl(polyethylene oxide) methyl)trisiloxane (74-90% w/w) and allyloxypolyethylene glycol methyl ether (14-20% w/w) were purchased from Dow Corning Toray (Japan). The PDMS included black silicon rubber to reduce background noise. Alexa Fluor® 488 AffiniPure Fab Fragment Goat Anti-Rabbit IgG (H + L), Alexa Fluor® 647 AffiniPure Fab Fragment Goat Anti-Rabbit IgG (H + L), and bovine serum albumin (BSA) were purchased from Jackson Immuno Research Laboratories Inc. (United States). Phosphate-buffered saline (PBS), fluorescein isothiocyanate (FITC) isomer I, dimethyl sulfoxide (DMSO), and lysozyme were purchased from Fujifilm Wako Pure Chemical Corporation (Osaka, Japan). Rabbit IgG and FITC-BSA conjugates were purchased from Sigma-Aldrich (St Louis, MO, USA).

Microfluidic device fabrication

For PEG-PDMS devices (Fig. 2b), the PDMS prepolymer with black silicon rubber was mixed with PEG functionalized silicone and curing agent at a ratio of 1000:5:100. It was then

Analyst

cured at 100 °C for 30 min to obtain PEG-PDMS sheets. The cured PEG-PDMS sheets and glass were plasma treated using a CUTE-1MP/R vacuum plasma system (Femto Science, Gwangju, Korea). The treatment time was fixed at 20 s and the power was set to 10 W. Oxygen or air was used as the process gas. Subsequently, the PEG-PDMS sheets were bonded to the glass and heated using a 75 °C hot plate to obtain PEG-PDMS devices.

The PDMS microfluidic devices were fabricated as described before.⁴⁵ The PDMS prepolymer with black silicone rubber was mixed with a curing agent in a ratio of 10:1. It was then cured at 80 °C for 60 min to obtain PDMS sheets. The PDMS sheets were then pasted onto the glass substrates without plasma treatment.

This device was designed with nine channels (Fig. 1c) to enable simultaneous analysis of nine groups of samples. The width of the channel was 200 μ m and the depth was 900 μ m.

Preparation of FITC-conjugated lysozyme (FITC-lysozyme)

FITC-lysozyme was synthesized according to a previous report.⁴⁶ A total of 2 mg lysozyme was weighed and dissolved in 1 mL carbonate buffer (0.1 M pH = 9); 1 mg FITC was dissolved in 1 mL dry DMSO; 100 μ L FITC solution was slowly added to 1 mL of lysozyme solution; the lysozyme solution was gently mixed as the FITC was added. The mixed solution was then incubated for 8 h at 4 °C. The crude product was purified on a PD MidiTrap G-25 column. The concentration of purified FITC-lysozyme was determined by measuring the absorbance using a BioSpectrometer (Eppendorf, Japan).

Evaluation of the adsorption of FITC-BSA and FITC-lysozyme to PDMS and PEG-PDMS microfluidic devices

Three sets of 20 μ L FITC-BSA and FITC-lysozyme solutions with 10⁻⁷, 10^{-7.5}, and 10⁻⁸ M were injected with a 30 mininterval period. After the final set of solutions was injected, the device was kept in the dark for 30 min. Fluorescence images were obtained using a portable analyzer. Afterwards, all channels were washed with 100 μ L PBS and the fluorescence images were obtained in the same manner. The fluorescence intensity was quantified using ImageJ software.

Demonstration of nonspecific adsorption between tracer and BSA

Tracer Alexa Fluor® 488-Fab (1.0 and 0.1 nM) were mixed with 0.1–0.7 wt% BSA and injected into the PDMS channel. Changes in fluorescence intensity and *P* with BSA concentration were measured using a portable analyzer. After 1 h of incubation, the channel was washed with 200 μ L PBS, and the fluorescence intensity was measured again.

Demonstration of FPIA in PDMS and PEG-PDMS microfluidic devices

For FPIA in PDMS microfluidic devices, a mixed solution of 0.007 nM-108 nM rabbit IgG (analyte/antigen), 0.1 nM or 1 nM Alexa Fluor 488-conjugated anti-Rabbit IgG Fab fragment (tracer/antibody) and 0.1 wt% blocking agent (BSA) was prepared. The mixed solution was incubated in the dark at 24 °C

for 60 min (1 nM tracer) or overnight (0.1 nM tracer). Subsequently, 20 μ L of the sample was injected into the PDMS device.

For FPIA in PEG-PDMS microfluidic devices, a mixed solution of 0.007 nM–108 nM rabbit IgG (analyte/antigen), 0.1 nM or 1 nM Alexa Fluor 488-conjugated anti-Rabbit IgG Fab fragment (tracer/antibody) was prepared. BSA was not added to the solution. The mixed solution was incubated in the dark at room temperature for 60 min (1 nM tracer) or overnight (0.1 nM tracer). Subsequently, 20 μ L of the sample was injected into the PDMS device.

In the FPIA measurement, P is expressed by the following equation:²³

$$P=\frac{I_{\parallel}-I_{\perp}}{I_{\parallel}+I_{\perp}}$$

where I_{\parallel} and I_{\perp} are the fluorescence intensities of the vertical and horizontal components of the emitted light, respectively.

The measured *P* was fitted using four-parameter logistic models⁴⁷ to obtain a standard curve f(x) and the fitting equation can be expressed as

$$P = f(x) = \frac{a-d}{1+\left(\frac{x}{c}\right)^b} + d$$

where x is the analyte concentration, a is the theoretical response at zero concentration, d is the theoretical response at an infinite concentration, c is the half-maximal inhibitory concentration (IC₅₀), and b is the slope factor.

The limit of detection (LOD) of the standard curve was calculated as

$$\text{LOD} = f^{-1}(P_0 + 3\sigma)$$

where $f^{-1}(P)$ is the inverse function of f(x) and is used to calculate the corresponding concentration *c* when a specific *P* is known. P_0 and σ represent the average and standard deviation of *P* at the lowest concentration condition respectively.

Results and discussion

Investigation of protein adsorption to PEG-PDMS device

PEG-PDMS microfluidic devices were fabricated by the same procedure except for the bonding process as PDMS. In the plasma treatment method, air plasma was used to avoid damage to the PEG functional groups (Fig. S1[†]). After plasma treatment, PEG-PDMS was heated at 75 °C for more than 19 h for strong bonding (Table S1[†]).

Subsequently, the protein adsorption to the microfluidic channel walls in PDMS and PEG-PDMS devices was investigated by using fluorescent-dye-conjugated proteins. Fig. 3a shows fluorescent images of the microfluidic channels loaded with FITC-BSA (pI = 5.1-5.5, negatively charged in pH 7.4) solutions before and after the washing process. In the PDMS device, the FITC-BSA fluorescence was retained after washing. In Fig. 3b, the fluorescence intensities for immersion times of

Paper



Fig. 3 Evaluation of the inhibitory adsorption effect. (a) Fluorescence images and (b) fluorescence intensity plot of FITC-BSA in PDMS and PEG-PDMS devices. PDMS, polydimethylsiloxane; PEG, polyethylene glycol.

30–90 min are plotted as a function of concentration. The result indicates that 38–79% of FITC-BSA adsorbed to the PDMS channel walls. On the other hand, in the PEG-PDMS device, the fluorescence of FITC-BSA drastically decreased after the washing process. This indicates that FITC-BSA was not adsorbed onto the PEG-PDMS channel walls. Higher molecular weight PEG effectively inhibits protein adsorption.⁴³ As protein adsorption was not observed in this experiment, the molecular weight of PEG in the PEG-functionalized silicone was considered sufficiently high to perform highly sensitive FPIA.

To confirm the versatility of the inhibition of protein adsorption onto PEG-PDMS, we examined the adsorption of

FITC-lysozyme (pI = 11.4; positively charged at pH 7.4). As shown in Fig. S2,† FITC-lysozyme did not absorb to PEG-PDMS channel walls while it adsorbed to PDMS ones. These results indicated that PEG-PDMS devices inhibited the nonspecific adsorption of proteins with both positive and negative charges. Therefore, we concluded that the FP assay could be conducted without blocking agents in the PEG-PDMS devices.

Demonstration of sensitivity enhancement in FPIA by using PEG-PDMS microfluidic device

In FPIA, tracer concentration is a key factor that limits sensitivity. Fig. 4a shows the theoretical curves of FPIA⁴⁸ composed of small tracers and large analytes at different tracer concentrations with $K_{\rm D} = 0.2$ nM. As the tracer concentration decreases, the dynamic range shifts to lower analyte concentrations. This indicated that lower tracer concentrations were more suitable for analyzing low-abundance analytes and provided a lower LOD.

Fig. 4b shows the standard curve of FPIA in PDMS devices with blocking agents (0.1% BSA). Although sigmoidal P increased with increasing analyte concentration, which is a typical response of FPIA, it was observed with a 1 nM tracer but not with a 0.1 nM tracer. With a 0.1 nM tracer, the P value increased with the decrease in analyte concentration in the lower concentration range (0.0016-0.026 nM). In addition, the P of all data points increased. This may result from two types of interference: nonspecific adsorption of the tracer to the blocking agent and the PDMS surface, which is insufficiently covered by the blocking agent. Further experiments (Fig. S4[†]) indicated that nonspecific adsorption of the tracer to the blocking agent and BSA autofluorescence caused the increase of P. However, the adsorption of the tracer on the PDMS surface was not significant. As a result, the standard curve at a 0.1 nM tracer concentration could not be fitted by the fourparameter logistic function.

Fig. 4c shows the standard curve for FPIA using PEG-PDMS devices. A sigmoidal *P* increase was observed with both 0.1 nM



Fig. 4 Sensitivity improvement of FPIA in the PEG-PDMS microfluidic device. (a) Theoretical FPIA standard curve with different tracer concentration. Dissociation constant (K_d) of tracer and analyte is 0.2 nM. FPIA standard curves in (b) PDMS devices with 0.1 wt% BSA and in (c) PEG-PDMS devices without BSA. PDMS, polydimethylsiloxane; PEG, polyethylene glycol; FPIA, fluorescence polarization immunoassay; BSA, bovine serum albumin.

Analyte	LOD (nM)	Ref.
Insulin	0.6	10
Glucagon	5	10
Lactoferrin	4.7	15
Anti-SARS-CoV-2 RBD IgG antibody	19	49
H5 avian influenza virus	45	45
Rabbit IgG	0.45	50
This study	0.25	

and 1 nM tracers. Compared to the results for the PDMS device, there was no significant increase in the baseline of *P* for the 0.1 nM concentration of the tracer concentration. This also supports the notion that nonspecific adsorption to the surface was suppressed by PEG-PDMS. FPIA cannot be demonstrated in PDMS devices using a 0.1 nM tracer but can be successfully demonstrated using PEG-PDMS devices. Using a PEG-PDMS microfluidic device with a 0.1 nM tracer, we obtained an LOD of 0.25 nM which is lower than the LOD in a PDMS device (0.81 nM) and lower than or comparable to a previous report of FP assays in microfluidic devices (Table 1). These results demonstrate that the use of PEG-PDMS devices and the removal of blocking agents improve the sensitivity of FPIA and increase the applicability of FPIA to analyze biomarkers at low cut-off values.

Conclusions

In this study, we report an improvement in the sensitivity of an FP assay using PEG surface modification. The PEG-PDMS devices obtained through this simple modification method effectively inhibited the nonspecific adsorption of proteins. Using these PEG-PDMS devices, it is possible to demonstrate the FP assay at low tracer concentrations without the use of blocking agents and achieve a higher sensitivity.

This study has significant implications for the quantitative analysis of low-abundance samples using FP assays. The improved sensitivity increases the potential of the FP assay for analyzing biomarkers at low cut-off values. This expands its application in clinical diagnostics and further enhances its importance for on-site analysis.

Author contributions

M.F. and A.H. conceived and designed the study. L.H. contributed to the data collection and analysis. M.F., A.H., and L.H. participated in discussions and provided constructive suggestions. M.F., A.H., and L.H. prepared initial drafts of the manuscript. Y.O., M.K., S.O., I.A., K.S., and M.T. critically reviewed and revised the manuscript. All the authors approved the final version of the manuscript.

Data availability

The data supporting this article have been included as part of the ESI.†

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

This work was supported by KAKEN-HI (Kiban A, 18H03912), the Strategic International Collaborative Research project promoted by the Ministry of Agriculture, Forestry and Fisheries, Tokyo, Japan, and the Cooperative Research Program of "Network Joint Research Center for Materials and Devices (MEXT)". Liu Hao acknowledges the GP-Chem program of Tohoku University.

References

- 1 D. M. Jameson and J. A. Ross, *Chem. Rev.*, 2010, **110**, 2685–2708.
- 2 M. C. Gutierrez, A. Gomez-Hens and D. Perez-Bendito, *Talanta*, 1989, **36**, 1187–1201.
- 3 M. D. Hall, A. Yasgar, T. Peryea, J. C. Braisted, A. Jadhav, A. Simeonov and N. P. Coussens, *Methods Appl. Fluoresc.*, 2016, 4, 022001.
- 4 C. Vinegoni, P. F. Feruglio, I. Gryczynski, R. Mazitschek and R. Weissleder, *Adv. Drug Delivery Rev.*, 2019, **151–152**, 262–288.
- 5 W. A. Lea and A. Simeonov, *Expert Opin. Drug Discovery*, 2011, 6, 17–32.
- 6 G. Seymour Shephard, Chem. Soc. Rev., 2008, 37, 2468-2477.
- 7 H. Zhang, S. Yang, K. De Ruyck, N. Beloglazova, S. A. Eremin, S. De Saeger, S. Zhang, J. Shen and Z. Wang, *TrAC, Trends Anal. Chem.*, 2019, **114**, 293–313.
- 8 C. Y. Lee, I. Degani, J. Cheong, R. Weissleder, J. H. Lee, J. Cheon and H. Lee, *Acc. Chem. Res.*, 2021, **54**, 3991–4000.
- 9 J. E. Adablah, Y. Wang, M. Donohue and M. G. Roper, *Anal. Chem.*, 2020, **92**, 8464–8471.
- 10 A. M. Schrell, N. Mukhitov and M. G. Roper, *Anal. Chem.*, 2016, **88**, 7910–7915.
- 11 L. F. Cheow, R. Viswanathan, C. S. Chin, N. Jennifer, R. C. Jones, E. Guccione, S. R. Quake and W. F. Burkholder, *Anal. Chem.*, 2014, 86, 9901–9908.
- 12 S. Okada, Y. Muto, B. Zhu, H. Ueda and H. Nakamura, *Anal. Chem.*, 2023, **95**, 6198–6202.
- 13 F. Gelen, M. Butz, E. J. Rees, M. Erdelyi, T. Moschetti, M. Hyvonen, J. B. Edel, C. F. Kaminski and F. Hollfelder, *Anal. Chem.*, 2017, 89, 1092–1101.
- 14 J. W. Choi, D. K. Kang, H. Park, A. J. Demello and S. I. Chang, *Anal. Chem.*, 2012, **84**, 3849–3854.

Analyst

- 15 X. Liu, H. Li, W. Jia, Z. Chen and D. Xu, *Lab Chip*, 2017, **17**, 178–185.
- 16 Y. Wang, D. I. Adeoye, Y. J. Wang and M. G. Roper, Anal. Chim. Acta, 2022, 1212, 339942.
- 17 V. K. Yadavalli and M. V. Pishko, *Anal. Chim. Acta*, 2004, 507, 123–128.
- 18 J. H. Kim, H. J. Shin, H. Cho, S. M. Kwak, H. Cho, T. S. Kim, J. Y. Kang and E. G. Yang, *Anal. Chim. Acta*, 2006, 577, 171–177.
- S. M. Mennen, C. Alhambra, C. L. Allen, M. Barberis, S. Berritt, T. A. Brandt, A. D. Campbell, J. Castañón, A. H. Cherney, M. Christensen, D. B. Damon, J. Eugenio De Diego, S. García-Cerrada, P. García-Losada, R. Haro, J. Janey, D. C. Leitch, L. Li, F. Liu, P. C. Lobben, D. W. C. Macmillan, J. Magano, E. McInturff, S. Monfette, R. J. Post, D. Schultz, B. J. Sitter, J. M. Stevens, I. I. Strambeanu, J. Twilton, K. Wang and M. A. Zajac, Org. Process Res. Dev., 2019, 23, 1213–1242.
- 20 J. Bajorath, Nat. Rev. Drug Discovery, 2002, 1, 882-894.
- 21 D. E. Ingber, Nat. Rev. Genet., 2022, 23, 467-491.
- A. L. Glieberman, B. D. Pope, J. F. Zimmerman, Q. Liu, J. P. Ferrier, J. H. R. Kenty, A. M. Schrell, N. Mukhitov, K. L. Shores, A. B. Tepole, D. A. Melton, M. G. Roper and K. K. Parker, *Lab Chip*, 2019, **19**, 2993–3010.
- 23 O. Wakao, Y. Fujii, M. Maeki, A. Ishida, H. Tani, A. Hibara and M. Tokeshi, *Anal. Chem.*, 2015, 87, 9647– 9652.
- A. Nakamura, M. Aoyagi, M. Fukuyama, M. Maeki,
 A. Ishida, H. Tani, K. Shigemura, A. Hibara and
 M. Tokeshi, *ACS Food Sci. Technol.*, 2021, 1, 1623–1628.
- 25 K. Takahashi, S. Chida, T. Suwatthanarak, M. Iida, M. Zhang, M. Fukuyama, M. Maeki, A. Ishida, H. Tani, T. Yasui, Y. Baba, A. Hibara, M. Okochi and M. Tokeshi, *Lab Chip*, 2022, 22, 2971–2977.
- 26 K. Nishiyama, M. Fukuyama, M. Maeki, A. Ishida, H. Tani,A. Hibara and M. Tokeshi, *Sens. Actuators, B*, 2021, 326, 128982.
- 27 J. C. McDonald, D. C. Duffy, J. R. Anderson, D. T. Chiu, H. Wu, O. J. A. Schueller and G. M. Whitesides, *Electrophoresis*, 2000, 21, 27–40.
- 28 S. K. Sia and G. M. Whitesides, *Electrophoresis*, 2003, 24, 3563-3576.
- 29 J. Zhou, D. A. Khodakov, A. V. Ellis and N. H. Voelcker, *Electrophoresis*, 2012, **33**, 89–104.
- 30 A. Fiene, Y. Baqi, J. Lecka, J. Sévigny and C. E. Müller, *Analyst*, 2015, **140**, 140–148.

- 31 E. A. Kumar, C. D. Charvet, G. L. Lokesh and A. Natarajan, *Anal. Biochem.*, 2011, **411**, 254–260.
- 32 C. I. Rogers, J. V. Pagaduan, G. P. Nordin and A. T. Woolley, *Anal. Chem.*, 2011, 83, 6418–6425.
- 33 J. Liu, X. Sun and M. L. Lee, Anal. Chem., 2007, 79, 1926– 1931.
- 34 M. Á. Sentandreu, L. Aubry, F. Toldrá and A. Ouali, *Eur. Food Res. Technol.*, 2007, **224**, 623–628.
- 35 W. Y. Craig, S. E. Poulin, M. F. Collins, T. B. Ledue and R. F. Ritchie, *J. Immunol. Methods*, 1993, **158**, 67–76.
- 36 Y. L. Jeyachandran, E. Mielczarski, B. Rai and J. A. Mielczarski, *Langmuir*, 2009, 25, 11614–11620.
- 37 J. N. Klatt, T. Hutzenlaub, T. Subkowski, T. Müller, S. Hennig, R. Zengerle and N. Paust, ACS Appl. Polym. Mater., 2021, 3, 3278–3286.
- 38 Y. L. Jeyachandran, J. A. Mielczarski, E. Mielczarski and B. Rai, J. Colloid Interface Sci., 2010, 341, 136–142.
- 39 S. R. J. Hoare, SLAS Discovery, 2021, 26, 835–850.
- 40 M. Fukuyama, M. Tokeshi, M. A. Proskurnin and A. Hibara, *Lab Chip*, 2018, **18**, 356–361.
- 41 S. Sugiura, J. Edahiro, K. Sumaru and T. Kanamori, *Colloids Surf.*, *B*, 2008, **63**, 301–305.
- 42 H. P. Long, C. C. Lai and C. K. Chung, Surf. Coat. Technol., 2017, 320, 315–319.
- 43 S. I. Jeon, J. H. Lee, J. D. Andrade and P. G. De Gennes, J. Colloid Interface Sci., 1991, 142, 149–158.
- 44 O. Wakao, K. Satou, A. Nakamura, P. A. Galkina,
 K. Nishiyama, K. Sumiyoshi, F. Kurosawa, M. Maeki,
 A. Ishida, H. Tani, M. A. Proskurnin, K. Shigemura,
 A. Hibara and M. Tokeshi, *Lab Chip*, 2019, **19**, 2581–2588.
- 45 K. Nishiyama, Y. Takeda, M. Maeki, A. Ishida, H. Tani, K. Shigemura, A. Hibara, Y. Yonezawa, K. Imai, H. Ogawa and M. Tokeshi, *Sens. Actuators, B*, 2020, **316**, 128160.
- 46 M. Takano, Y. Koyama, H. Nishikawa, T. Murakami and R. Yumoto, *Eur. J. Pharmacol.*, 2004, **502**, 149–155.
- 47 S. K. Kim, S. H. Hwang and H. B. Oh, *BioChip J.*, 2016, **10**, 346–353.
- 48 D. S. Smith and S. A. Eremin, Anal. Bioanal. Chem., 2008, 391, 1499–1507.
- 49 K. Nishiyama, K. Takahashi, M. Fukuyama, M. Kasuya, A. Imai, T. Usukura, N. Maishi, M. Maeki, A. Ishida, H. Tani, K. Hida, K. Shigemura, A. Hibara and M. Tokeshi, *Biosens. Bioelectron.*, 2021, **190**, 113414.
- 50 M. Fukuyama, A. Nakamura, K. Nishiyama, A. Imai, M. Tokeshi, K. Shigemura and A. Hibara, *Anal. Chem.*, 2020, 92, 14393–14397.